Editorials Sulfonylureas as second line treatment for type 2 diabetes BMJ 2018; 362 doi: https://doi.org/10.1136/bmj.k3041 (Published 18 July 2018) Cite this as: BMJ 2018;362:k3041 Article Related content Metrics Responses Peer review Related articles Research Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study Published: 18 July 2018; BMJ 362 doi:10.1136/bmj.k2693 ResearchSulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events See more Offer histopathology trainees “golden hellos” to bolster numbers, says college BMJ September 18, 2018, 362 k3963; DOI: https://doi.org/10.1136/bmj.k3963 Government is urged to scrap visa cap for all foreign doctors after Brexit BMJ September 18, 2018, 362 k3961; DOI: https://doi.org/10.1136/bmj.k3961 US agency changes alcohol advice after doctor complains BMJ September 18, 2018, 362 k3957; DOI: https://doi.org/10.1136/bmj.k3957 Sarah Wells: striving for holistic care BMJ September 18, 2018, 362 k3587; DOI: https://doi.org/10.1136/bmj.k3587 Medical associate professions: how physician associate and similar roles are developing, and what that means for doctors BMJ September 18, 2018, 362 k3897; DOI: https://doi.org/10.1136/bmj.k3897
